Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity
Eduardo Zatarain‐Nicolás(Hospital General Universitario Gregorio Marañón), Teresa López‐Fernández(Hospital Universitario La Paz), Ana Martín‐Garcia(Complejo Hospitalario de Salamanca), Pilar Martı́n(Spanish National Centre for Cardiovascular Research), Borja Ibáñez(Spanish National Centre for Cardiovascular Research), Juan Cosı́n-Sales(Hospital Arnau de Vilanova), Cristina Mitroi(Hospital Universitario Puerta de Hierro Majadahonda), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Javier de Castro(Bayer (United States)), Vivencio Barrios(Apple (Israel)), Juan Antonio Virizuela(Hospital Universitario Virgen Macarena), Fátima Sánchez‐Cabo(Spanish National Centre for Cardiovascular Research)
Cited by 4
Related Papers
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
|European Heart Journal|2024|2.4k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k